Vertex Pharmaceuticals (VRTX) Current Deferred Revenue (2009 - 2017)

Vertex Pharmaceuticals' Current Deferred Revenue history runs 9 years deep, the most recent figure standing at $5.2 million for Q4 2017.

• In Q4 2017, Current Deferred Revenue fell 13.92% year-over-year to $5.2 million; the TTM figure through Dec 2017 stood at $5.2 million (down 13.92% YoY), while the FY2017 annual figure was $5.2 million, down 13.92% from the prior year.
• Current Deferred Revenue was $5.2 million for Q4 2017 at Vertex Pharmaceuticals, down from $13.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $35.5 million in Q1 2013 to a low of $5.2 million in Q4 2017.
• Historically, Current Deferred Revenue has averaged $17.5 million across 5 years, with a median of $15.4 million in 2015.
• The sharpest annual moves came in 2016 and 2017: Current Deferred Revenue slumped 63.15% in 2016, then jumped 40.62% in 2017.
• A 5-year view of Current Deferred Revenue shows it stood at $21.5 million in 2013, then dropped by 18.79% to $17.5 million in 2014, then slipped by 6.71% to $16.3 million in 2015, then plunged by 63.15% to $6.0 million in 2016, then decreased by 13.92% to $5.2 million in 2017.
• The last three Current Deferred Revenue figures came in at $5.2 million (Q4 2017), $13.0 million (Q3 2017), and $7.3 million (Q2 2017), per Business Quant data.